证券代码：603205 证券简称：健尔康 公告编号：2025-002 健尔康医疗科技股份有限公司 第二届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 以及主要股东之间不存在利害关系、重大业务往来或其他可能妨碍其独立性的关 系。公司独立董事具备独立性，能够有效履行独立董事职责，为公司的规范运作 和健康发展发挥积极作用。 表决结果：9 票同意、0 票反对、0 票弃权。 健尔康医疗科技股份有限公司（以下简称"公司"）第二届董事会第十三次 会议于 2025 年 4 月 22 日以现场结合通讯的方式在公司会议室召开，会议通知于 2025 年 4 月 12 日以书面方式送达。本次会议由董事长陈国平先生主持，应到董 事 9 人，实到董事 9 人，公司监事和高级管理人员列席了会议。本次董事会的召 集、召开和表决程序符合《中华人民共和国公司法》等有关法律、法规及《公司 章程》的规定。 二、董事会会议审议情况 经全体董事逐项审议，会议表决情况如下： （一）审议通过《关于公司<2024 年度总经 ...

证券代码：603205 证券简称：健尔康 公告编号：2025-004 健尔康医疗科技股份有限公司 2024 年年度利润分配及公积金转增股本方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例：A 股每股派发现金红利 0.351 元（含税），以资本公 积转增股本方式向全体股东每股转增 0.3 股。 本次利润分配及公积金转增股本以实施权益分派股权登记日登记的总 股本为基数，具体日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股 分配、转增比例不变，相应调整分配、转增总额，并将在相关公告中披露。 本次利润分配方案不触及《上海证券交易所股票上市规则（2024 年 4 月修订）》第 9.8.1 条第一款第（八）项规定的可能被实施其他风险警示的情形。 本次利润分配和资本公积金转增股本方案尚需提交 2024 年年度股东 大会审议通过后方可实施。 一、利润分配方案内容 2、公司不送红股，拟以资本公积向全体股东每10股转增3股。截至2025年4 月22日，公司总股本为 ...

中信建投证券股份有限公司 关于健尔康医疗科技股份有限公司 2025年度日常关联交易预计的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐人"）作 为健尔康医疗科技股份有限公司（以下简称"健尔康"或"公司"）首次公开发 行股票并在主板上市的保荐人，根据《证券发行上市保荐业务管理办法》《上海 证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 5 号—— 交易与关联交易》等相关法律、法规和规范性文件的规定，对健尔康 2025 年度 日常关联交易预计事项进行了审慎核查，具体情况如下： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 2025 年 4 月 22 日，公司召开了第二届董事会第十三次会议，以 8 票同意、 0 票反对、0 票弃权、1 票回避的表决结果，审议通过了《关于公司<2025 年度日 常关联交易预计>的议案》，关联董事陈国平先生回避表决。独立董事 2025 年第 一次专门会议以全票同意审议通过了该事项，公司监事会经审核发表了审核意见， 保荐人出具了核查意见。 本次日常关联交易预计事项无需提交股东大会审议。 （二）前次日常关联交易的预计和执行情况 三、关联交 ...

独立董事 2024年度沐职报告 健尔康医疗科技股份有限公司 作为公司第二届董事会独立董事,2024年度,本人严格按照《公司法》 《证券法》《上市公司治理准则》《上市公司独立董事管理办法》和《上海证 券交易所股票上市规则》等相关法律法规和《公司章程》《公司独立董事工作 制度》的规定,切实履行独立董事的各项职责和义务,认真行使公司和股东所 赋予的权利,积极参加公司股东大会、董事会及专门委员会会议,认真审议公 司各项议案,对公司董事会审议的相关重大事项发表了公正、客观的独立意见, 努力维护公司和全体股东的利益。现将本人2024年度的履职情况报告如下: - 一、独立董事的基本情况 (二) 独立性情况说明 作为公司独立董事,本人及直系亲属、主要社会关系均不在公司或其附属 企业任职,且未在公司关联企业任职,具备中国证券监督管理委员会《上市公 司独立董事管理办法》《公司章程》和《公司独立董事管理办法》所要求的独 立性和担任公司独立董事的任职资格。在履职过程中能够确保客观、独立的专 业判断,维护全体股东特别是中小投资者的利益,不存在影响独立性的情况。 二、独立董事年度履职概况 (一) 2024 年度出席会议的情况 2024年 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 240,894,839.46, representing a year-on-year increase of 13.69% compared to CNY 211,887,752.70 in the same period last year[4]. - The net profit attributable to shareholders for the same period was CNY 28,805,066.25, reflecting a growth of 15.42% from CNY 24,956,173.02 in the previous year[4]. - Basic and diluted earnings per share decreased by 14.29%, from CNY 0.28 to CNY 0.24[4]. - Total operating revenue for Q1 2025 reached RMB 240,894,839.46, an increase of 13.7% compared to RMB 211,887,752.70 in Q1 2024[18]. - Net profit for the period was ¥28,805,066.25, up from ¥24,956,173.02, reflecting a growth of about 15%[20]. - Operating profit rose to ¥32,715,103.52 compared to ¥28,171,319.31, indicating an increase of approximately 16%[19]. - Operating profit for Q1 2025 was ¥29,772,799.43, up from ¥26,965,285.49 in Q1 2024, reflecting a growth of 6.69%[30]. - Net profit for Q1 2025 was ¥26,594,413.59, compared to ¥24,048,747.31 in Q1 2024, representing an increase of 10.58%[30]. Cash Flow and Assets - The net cash flow from operating activities decreased significantly by 39.55%, amounting to CNY 38,976,102.77, down from CNY 64,481,585.29 in the previous year[4]. - Cash and cash equivalents decreased to RMB 642,741,803.27 as of March 31, 2025, down from RMB 721,814,787.44 at the end of 2024, representing a decline of 10.9%[13]. - The company experienced a decrease in cash flow primarily due to reduced sales collections compared to the previous year[7]. - The net cash flow from operating activities for Q1 2025 was ¥38,788,093.83, down from ¥58,408,382.51 in Q1 2024, a decrease of 33.67%[31]. - Total assets at the end of the reporting period were CNY 1,596,222,114.18, a slight increase of 0.36% from CNY 1,590,569,355.28 at the end of the previous year[5]. - Total assets as of March 31, 2025, amounted to RMB 1,596,222,114.18, slightly up from RMB 1,590,569,355.28 at the end of 2024[15]. - Total liabilities decreased to RMB 145,863,095.83 from RMB 170,433,957.25, a decrease of 14.5%[15]. - Total liabilities decreased to ¥210,203,686.37 from ¥230,676,594.72, a reduction of 8.87%[27]. - Cash flow from operating activities decreased to ¥38,976,102.77 from ¥64,481,585.29, a decline of about 40% year-over-year[22]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 22,633[8]. - The largest shareholder, Chen Guoping, holds 52,110,000 shares, accounting for 43.43% of the total shares[9]. - There were no significant changes in shareholder structure or related party transactions reported[10]. Research and Development - Research and development expenses increased to ¥9,493,619.86 from ¥8,037,836.61, marking a rise of about 18%[19]. - Research and development expenses for Q1 2025 were ¥8,960,414.74, compared to ¥7,488,342.76 in Q1 2024, an increase of 19.66%[29]. Other Financial Metrics - The company recognized non-recurring gains and losses totaling CNY 1,007,423.09 for the period[7]. - The company reported a net profit margin improvement, with retained earnings increasing to RMB 562,833,104.59 from RMB 534,028,038.34[15]. - Total operating costs increased to ¥207,230,900.09 from ¥186,209,337.83, representing an increase of approximately 11% year-over-year[19]. - The company experienced a net cash outflow from investing activities of ¥117,936,051.43, compared to an outflow of ¥12,551,473.04 in the previous year[23]. - The company has not disclosed any new product developments or market expansion strategies during the reporting period[11].

Dividend and Share Capital - The company plans to distribute a cash dividend of 3.51 RMB per 10 shares, totaling 42,120,000 RMB, which accounts for 35.04% of the net profit attributable to shareholders for the fiscal year 2024[6]. - The company intends to increase its total share capital from 120,000,000 shares to 156,000,000 shares by issuing 3 additional shares for every 10 shares held[6]. - The company’s total share capital as of April 22, 2025, is projected to be 156,000,000 shares after the proposed capital increase[6]. Financial Performance - The company’s operating revenue for 2024 was CNY 1,045,764,120.28, representing a slight increase of 1.18% compared to CNY 1,033,526,739.74 in 2023[24]. - Net profit attributable to shareholders decreased by 2.69% to CNY 120,218,925.03 from CNY 123,546,246.16 in the previous year[26]. - The net profit after deducting non-recurring gains and losses fell by 4.41% to CNY 115,206,176.44 compared to CNY 120,523,820.90 in 2023[27]. - The net cash flow from operating activities decreased by 10.59% to CNY 141,096,493.27, primarily due to increased cash expenses related to operations and taxes[27]. - Shareholders' equity increased by 56.17% to CNY 1,420,135,398.03, while total assets rose by 42.84% to CNY 1,590,569,355.28, mainly due to the successful IPO and the inflow of raised funds[27]. - Basic earnings per share decreased by 7.30% to CNY 1.27 from CNY 1.37 in 2023[25]. - The weighted average return on equity decreased by 3 percentage points to 11.60% from 14.60% in the previous year[25]. Audit and Compliance - The company has received a standard unqualified audit report from Tianheng Accounting Firm, ensuring the accuracy and completeness of the financial report[5]. - The company has confirmed that there are no non-operational fund occupations by controlling shareholders or related parties[8]. - The company has not violated any decision-making procedures regarding external guarantees[8]. - The company’s financial report has been declared true, accurate, and complete by its responsible executives[5]. - The company has confirmed that all board members attended the board meeting, ensuring collective responsibility for the report's content[4]. Risk Management - The company has outlined potential risks in its report, advising investors to review the "Management Discussion and Analysis" section for detailed risk factors[9]. - The company emphasizes that forward-looking statements do not constitute substantive commitments to investors, highlighting the importance of investment risk awareness[7]. - The company faces risks related to changes in industry regulations, which could impact its domestic sales of medical dressings[128]. - The company is exposed to foreign market risks, including political instability and trade policy changes that could affect its overseas operations[129]. - The company’s profitability may be impacted by fluctuations in raw material prices, particularly for cotton and petroleum-based products[129]. - The company is monitoring the progress of US-China trade negotiations to mitigate potential impacts on its export business[131]. Research and Development - The company invested 40.72 million yuan in R&D during the reporting period, an increase of 11.30% compared to the previous year[39]. - The company holds a total of 20 invention patents, 30 utility model patents, and 7 design patents, enhancing its competitive edge in technology development[39]. - The company aims to enhance its R&D investment in medical dressings, high polymer consumables, and cleaning and disinfection products, while exploring new fields such as rehabilitation and health consumption[118]. - The company plans to increase investment in technology research and development, focusing on automation and standardization to improve core competitiveness in the medical dressing industry[124]. - The company will increase its R&D efforts to expand its product range, which currently includes five major categories: surgical consumables, nursing products, cleaning and disinfection products, high polymer and auxiliary products, and others[123]. Market and Sales Strategy - The company experienced a decline in domestic sales, which was offset by steady growth in overseas sales, contributing to the overall revenue stability[24]. - The company generated overseas main business revenue of 920 million yuan, an increase of 6.59% compared to the same period last year[40]. - The company’s sales strategy includes OEM direct sales to overseas brand merchants, primarily targeting developed markets like the US and Europe[67]. - The company’s domestic sales include direct sales and distribution, with a small portion sold directly to end customers through e-commerce platforms[68]. - The company has established long-term strategic partnerships with several international medical dressing brands, enhancing its market reach across continents[73]. Corporate Governance - The company has established a modern corporate governance structure, holding 4 shareholder meetings and 11 board meetings during the reporting period[37]. - The company’s governance practices comply with relevant laws and regulations, with no significant discrepancies noted[136]. - The board of directors consists of 9 members, including 3 independent directors with expertise in law and accounting[136]. - The company has established specialized committees, including a strategy committee and an audit committee, to enhance governance and decision-making processes[135]. Environmental Responsibility - The company invested CNY 14.58 million in environmental protection during the reporting period[175]. - The wastewater treatment facility has a maximum capacity of 3,000 tons per day and is operating normally[179]. - The company has implemented effective measures for handling major pollutants, including low-nitrogen treatment for exhaust gases and a self-built wastewater treatment station[177]. - The company has not faced any environmental violations or penalties during the reporting period[176]. Employee and Management Compensation - The company has implemented a cash dividend policy that prioritizes reasonable returns to public shareholders, with annual distributions based on available profits[161]. - Total remuneration for directors, supervisors, and senior management amounted to 6.197 million yuan for the reporting period[144]. - The compensation policy for directors and senior management is aligned with the company's operational performance and local industry standards[144]. - The company emphasizes a performance-based compensation structure that aligns with its strategic goals and enhances employee motivation[159]. Future Outlook - Future guidance indicates a projected growth rate of approximately 10% year-over-year for the next fiscal year[141]. - The management emphasized the importance of strategic partnerships to enhance distribution channels and market reach[141]. - Overall, the company remains optimistic about its growth trajectory and is committed to delivering shareholder value through strategic initiatives[141].

2025 年 4 月 22 日 董事会对在任独立董事独立性情况评估的专项意见 健尔康医疗科技股份有限公司（以下简称"公司"）根据《上 市公司独立董事管理办法》《上海证券交易所上市公司自律监管指引 第 1 号——规范运作》等要求，结合各位在任独立董事自查的结果 和公司评估和调查的情况，出具对在任独立董事独立性情况评估的 专项意见如下： 公司三位独立董事董寅生先生、胡晓明先生、张建先生，未在 公司担任除独立董事以外的任何职务，也未在公司主要股东公司担 任任何职务，与公司以及主要股东之间不存在利害关系或其他可能 妨碍其进行独立客观判断的关系，符合《公司法》《上市公司治理准 则》和《上市公司独立董事管理办法》等法律法规以及《公司章程》 对独立董事的任职要求，在 2024 年度不存在影响独立性的情形。 健尔康医疗科技股份有限公司董事会 ...

健尔康医疗科技股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 拟续聘的会计师事务所名称：天衡会计师事务所（特殊普通合伙） 一、拟续聘会计师事务所的基本情况 证券代码：603205 证券简称：健尔康 公告编号：2025-006 （一）机构信息 1.基本信息 | 事务所名称 | 天衡会计师事务所（特殊普通合伙） | | | --- | --- | --- | | 成立日期 | 2013 年 11 月 4 日 | | | 组织形式 | 特殊普通合伙企业 | | | 注册地址 | 南京市建邺区江东中路 106 号 1907 室 | | | 首席合伙人 | 郭 澳 2024 年末合伙人数量 | 85 | | 上年末执业人员数量 | 注册会计师人数 | 386 | | | 签署过证券业务审计报告的注册会计师 人数 | 227 | 天衡会计师事务所（特殊普通合伙）（以下简称：天衡会计师事务所） 2024 年度经审计的业务收入总额为人民币 52,937.55 万元,其中审计业务收入为人 ...

证券代码：603205 证券简称：健尔康 公告编号：2025-005 健尔康医疗科技股份有限公司 关于2025年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 根据《上海证券交易所股票上市规则》《上海证券交易所上市公司自律 监管指引第 5 号——交易与关联交易》等有关规定，公司本次日常关联交易预计 事项无需提交股东大会审议。 公司本次预计日常关联交易不会对关联方形成依赖，不影响公司的独立 性，不会对公司的持续经营能力、盈利能力及资产状况造成重大影响。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 公司于 2025 年 4 月 11 日召开第二届董事会独立董事 2025 年第一次专门会 议，审议通过了《关于公司<2025 年度日常关联交易预计>的议案》，此议案获 得全体独立董事一致表决通过。独立董事认为公司 2024 年已发生的日常关联交 易和 2025 年度日常关联交易预计符合公司日常经营需要，交易定价符合市场定 价原则，不存在损害公司利益及全体股东特别是中小股东利益的情 ...